Switch theme
Sign up to access all valuation multiples
PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's gross profits are derived from the distribution and logistics segments. The company operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.
1966
16.7K+
LTM Revenue $2.1B
LTM EBITDA $309M
$4.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kalbe Farma has a last 12-month revenue (LTM) of $2.1B and a last 12-month EBITDA of $309M.
In the most recent fiscal year, Kalbe Farma achieved revenue of $2.0B and an EBITDA of $283M.
Kalbe Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kalbe Farma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | XXX | $2.0B | XXX | XXX | XXX |
| Gross Profit | $829M | XXX | $795M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $309M | XXX | $283M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $265M | XXX | $250M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $207M | XXX | $199M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kalbe Farma's stock price is IDR 1515 (or $0).
Kalbe Farma has current market cap of IDR 70.92T (or $4.4B), and EV of IDR 66.77T (or $4.1B).
See Kalbe Farma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.1B | $4.4B | XXX | XXX | XXX | XXX | $0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kalbe Farma has market cap of $4.4B and EV of $4.1B.
Kalbe Farma's trades at 2.0x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate Kalbe Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kalbe Farma has a P/E ratio of 21.0x.
See valuation multiples for Kalbe Farma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.4B | XXX | $4.4B | XXX | XXX | XXX |
| EV (current) | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.3x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 15.5x | XXX | 16.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.0x | XXX | 21.9x | XXX | XXX | XXX |
| EV/FCF | 23.7x | XXX | 18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKalbe Farma's last 12 month revenue growth is 7%
Kalbe Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
Kalbe Farma's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kalbe Farma's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kalbe Farma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kalbe Farma acquired XXX companies to date.
Last acquisition by Kalbe Farma was XXXXXXXX, XXXXX XXXXX XXXXXX . Kalbe Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kalbe Farma founded? | Kalbe Farma was founded in 1966. |
| Where is Kalbe Farma headquartered? | Kalbe Farma is headquartered in Indonesia. |
| How many employees does Kalbe Farma have? | As of today, Kalbe Farma has 16.7K+ employees. |
| Is Kalbe Farma publicy listed? | Yes, Kalbe Farma is a public company listed on IDX. |
| What is the stock symbol of Kalbe Farma? | Kalbe Farma trades under KLBF ticker. |
| When did Kalbe Farma go public? | Kalbe Farma went public in 1991. |
| Who are competitors of Kalbe Farma? | Similar companies to Kalbe Farma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kalbe Farma? | Kalbe Farma's current market cap is $4.4B |
| What is the current revenue of Kalbe Farma? | Kalbe Farma's last 12 months revenue is $2.1B. |
| What is the current revenue growth of Kalbe Farma? | Kalbe Farma revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Kalbe Farma? | Current revenue multiple of Kalbe Farma is 2.0x. |
| Is Kalbe Farma profitable? | Yes, Kalbe Farma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kalbe Farma? | Kalbe Farma's last 12 months EBITDA is $309M. |
| What is Kalbe Farma's EBITDA margin? | Kalbe Farma's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Kalbe Farma? | Current EBITDA multiple of Kalbe Farma is 13.3x. |
| What is the current FCF of Kalbe Farma? | Kalbe Farma's last 12 months FCF is $173M. |
| What is Kalbe Farma's FCF margin? | Kalbe Farma's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Kalbe Farma? | Current FCF multiple of Kalbe Farma is 23.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
